#Australia #CSL #Pharma 4.0 #Facility of the Year #Broadmeadows

CSL's Broadmeadows Facility Triumphs at the 2025 Facility of the Year Awards

In an impressive recognition of excellence and innovation, CSL's base fractionation facility located in Broadmeadows, Australia, has been honored as the Overall Winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE). This accolade not only highlights CSL's dedication to responsible manufacturing practices but also indicates a significant advancement in the field of biopharmaceuticals.

A Forward-Thinking Approach to Plasma Manufacturing

The Broadmeadows facility stands as a beacon of modern pharmaceutical manufacturing, integrating Pharma 4.0™ principles with environmentally sustainable design. Designed specifically to optimize the production of plasma-derived therapies that treat critical conditions such as immune system deficiencies, neurological issues, and burn recovery, this facility employs a groundbreaking hybrid manufacturing platform.

Its innovative features include:

• - Advanced Automation: Utilizing state-of-the-art robotics and equipment, the facility ensures efficient production processes.
• - Real-time Monitoring: A robust digital twin infrastructure allows for continuous monitoring, ensuring optimal efficiency throughout the manufacturing process.
• - Modular Design: This feature guarantees the facility can scale its production capabilities based on demand, adapting to changing requirements.

With these cutting-edge technologies, CSL has dramatically increased its plasma processing capacity to handle over 10 million liters annually, thus enhancing productivity and enabling the provision of life-saving treatments to a larger patient population.

Recognizing Community and Team Efforts

Andrew Hodder, VP Manufacturing and Site Head at Broadmeadows, emphasized that this prestigious award is a testament to the hard work and collaboration of the entire CSL team across the globe. The dedication exhibited by employees at all levels contributes to the facility's success and its recognition as a global benchmark in biopharmaceutical manufacturing.

"This award not only underscores our commitment to innovation and operational excellence but also enhances our reputation as a leader in sustainable manufacturing,” Hodder stated.

Sustainable Manufacturing Practices

A key aspect of CSL's strategy is its unwavering focus on sustainability. The sustainable infrastructure of the Broadmeadows facility aligns with CSL's vision of responsible innovation. Noteworthy environmental initiatives include:

• - Reusable Filters: These contribute to reducing waste and lowering the carbon footprint.
• - Energy-efficient Systems: Designed to minimize energy consumption, the systems ensure that production processes are both effective and environmentally friendly.
• - Automated Warehousing: The facility features an entirely automated warehouse operated by robotic vehicles, streamlining material handling processes and further enhancing efficiency.

Jeffrey Ball, Chief Sustainability Officer and Senior Vice President for EHS Strategy at CSL, remarked, "By marrying automation with sustainable design, we have created a future-ready facility that not only adheres to the highest standards in pharmaceutical manufacturing but also sets a precedent for the industry."

Building on Previous Achievements

The recognition of the Broadmeadows facility builds on its earlier honor in May 2025, when it received the ISPE FOYA award in the Pharma 4.0™ category. This acknowledgment pinpointed CSL's pioneering use of digital technologies and automation in transforming pharmaceutical manufacturing practices.

About CSL

CSL (ASX: CSL; USOTC: CSLLY) operates as a leading global biopharmaceutical company, featuring a diverse range of life-saving medicines designed to treat various medical conditions, including treatments for hemophilia, immune deficiencies, and vaccines to prevent influenza. Since its inception in 1916, CSL has dedicated itself to the mission of saving lives through cutting-edge technologies. With a workforce exceeding 29,000 employees worldwide, CSL provides critical products to patients across more than 100 countries.

To delve deeper into CSL's inspiring journey in biotechnology, visit CSL.com/Vita for compelling stories. For further information regarding CSL and its array of life-saving products, visit CSL.com.